Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio
Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.
Deutsche Bank has upgraded its rating on Eli Lilly and Co (LLY.US) from "hold" to "buy" with a target price increase from $725 to $1025.
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Express News | JMP Securities Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $86
Structure Therapeutics Analyst Ratings
Structure Therapeutics Reports Q2 Results
Promising Outlook for Structure Therapeutics With Strong Pipeline and Financial Stability
Why Are Hedge Funds Bullish on Structure Therapeutics Inc. (GPCR) Now?
S&P rises over 2%, the best in nearly two years, with chip stocks up about 7%, Nasdaq and Chinese stocks up 2.8%, and US Treasury yields and the yen falling for three consecutive days.
The latest employment data alleviates concerns over the US economy, and US stocks rose more than 1.7%. Nvidia's stock rose more than 6%, and Tesla, Alibaba, PDD Holdings, and Tencent ADR rose more than 3%. Bullish on weight loss drug reports, Eli Lilly and Co's stock rose more than 13%, and Novo-Nordisk A/S's US stock rose nearly 8%. The 10-year US Treasury yield rose above 4%, and short-term bond yields rose by 10 basis points. Oil prices rose for the third consecutive day, gold halted its five-day decline, and digital currency had a big increase.
Express News | Structure Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Express News | Structure Therapeutics : Cash Balance of $927.1 Mln Expected to Fund Projected Operations and Key Clinical Milestones Through at Least 2027
Express News | Structure Therapeutics Inc: Obesity Pipeline Consists of Four Oral Small Molecule Programs Targeting GLP-1, Gip, Amylin and Apj Receptors
Express News | Structure Therapeutics : Oral Small Molecule Amylin Receptor Agonist Development Candidate Expected to Be Selected in Q4 of 2024
Structure Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Express News | Structure Therapeutics Inc. Q2 Net Income USD -26.034 Million
Express News | Structure Therapeutics Inc. Q2 Operating Expenses USD 33.316 Million
Breaking doubts! The 'weight loss miracle drug' continues to be hot, and Eli Lilly and Co's Q2 performance exceeds expectations and guidance is raised again.
$Eli Lilly and Co (LLY.US)$ Eli Lilly announced its Q2 results on Thursday. According to the data, the company's Q2 revenue was $11.3 billion, a year-on-year increase of 36.0%, better than market expectations; EPS was $3.92, also better than market expectations. thanks to the popularity of the popular weight loss drug Zepbound, the company raised its 2024 revenue guidance for the second time this year. Data showed that Zepbound sales in the second quarter were $1.2 billion, exceeding market expectations of $0.819 billion. Eli Lilly currently expects full-year revenue to be between $45.4 billion and $46.6 billion, higher than previous expectations.
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $136
No Data